Sosei Group Corporation Stock price

Equities

4565

JP3431300007

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-03-28 am EDT 5-day change 1st Jan Change
1,621 JPY +1.19% Intraday chart for Sosei Group Corporation +1.69% +14.07%
Sales 2023 12.77B 84.29M Sales 2024 * 34.93B 231M Capitalization 143B 946M
Net income 2023 -7.91B -52.25M Net income 2024 * 839M 5.54M EV / Sales 2023 11.9 x
Net Debt 2023 24.91B 164M Net Debt 2024 * 19.22B 127M EV / Sales 2024 * 4.65 x
P/E ratio 2023
-16.3 x
P/E ratio 2024 *
68.1 x
Employees 350
Yield 2023 *
-
Yield 2024 *
-
Free-Float 88.87%
More Fundamentals * Assessed data
Dynamic Chart
Sosei Shareholders Greenlight Name Change, Top Management Appointments MT
Sosei Heptares Begins Phase 1 Trial for Novel Inflammatory Bowel Disease Treatment MT
Sosei Group Corporation Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease CI
Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease CI
Jefferies Adjusts Sosei Group’s Price Target to 2,100 Yen From 1,800 Yen, Keeps at Buy MT
Sosei Group, Boehringer Ingelheim Enter Into License Deal for Schizophrenia Symptoms MT
Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-In-Class Treatments Targeting All Symptoms of Schizophrenia CI
Boehringer Ingelheim and Sosei Group Corporation Enter Exclusive Option-To- License Agreement CI
Japanese Shares Close Lower But Hit Fresh 52-Week High on US Rate Cut Assurance MT
Sosei Group to Get $2.5 Million Milestone Payment from Formosa Pharmaceuticals MT
Sosei Group Corporation to Receive $2.5 Million Payment from Formosa Pharmaceuticals CI
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
Sosei Group Changes Names of Company, Subsidiaries MT
Transcript : Sosei Group Corporation, 2023 Earnings Call, Feb 13, 2024
Jefferies Adjusts Sosei Group's Price Target to 1,800 Yen From 1,700 Yen, Keeps at Buy MT
More news
1 day+1.19%
1 week+1.69%
Current month+11.33%
1 month+11.72%
3 months+11.56%
6 months+6.43%
Current year+14.07%
More quotes
1 week
1 559.00
Extreme 1559
1 652.00
1 month
1 423.00
Extreme 1423
1 826.00
Current year
1 296.00
Extreme 1296
1 826.00
1 year
1 296.00
Extreme 1296
3 185.00
3 years
991.00
Extreme 991
3 185.00
5 years
991.00
Extreme 991
3 185.00
10 years
463.50
Extreme 463.5
6 545.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 40 17-09-19
Founder 74 90-06-21
Director of Finance/CFO - 22-03-23
Members of the board TitleAgeSince
Founder 74 90-06-21
Director/Board Member 66 19-03-26
Director/Board Member 58 20-03-24
More insiders
Date Price Change Volume
24-03-28 1,621 +1.19% 990 700
24-03-27 1,602 -0.74% 1,054,800
24-03-26 1,614 +2.28% 1,128,900
24-03-25 1,578 -0.75% 736,100
24-03-22 1,590 -0.25% 753,600

Delayed Quote Japan Exchange, March 28, 2024 at 02:00 am EDT

More quotes
Sosei Group Corporation is a holding company primarily engaged in the biopharmaceutical business. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1,602 JPY
Average target price
2,112 JPY
Spread / Average Target
+31.87%
Consensus
  1. Stock
  2. Equities
  3. Stock Sosei Group Corporation - Japan Exchange